TW200745126A - Bicyclic heteroaryl derivatives as cannabinoid receptor modulators - Google Patents

Bicyclic heteroaryl derivatives as cannabinoid receptor modulators

Info

Publication number
TW200745126A
TW200745126A TW096106748A TW96106748A TW200745126A TW 200745126 A TW200745126 A TW 200745126A TW 096106748 A TW096106748 A TW 096106748A TW 96106748 A TW96106748 A TW 96106748A TW 200745126 A TW200745126 A TW 200745126A
Authority
TW
Taiwan
Prior art keywords
cannabinoid
cannabinoid receptor
receptor modulators
disorders
bicyclic heteroaryl
Prior art date
Application number
TW096106748A
Other languages
Chinese (zh)
Inventor
Mrinalkanti Kundu
Neelima Khairatkar-Joshi
Suhas Mangesh Nadkarni
Rameshwar Madhavrao Pansare
Pallavi Karnik
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of TW200745126A publication Critical patent/TW200745126A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

The present invention relates to novel bicyclic derivatives as cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, smoking cessation, alcohol dependency, depression, and attention deficit hyperactivity disorder). Pharmaceutical compositions containing the described compounds, which can be used for the treatment of diseases, condition and/or disorders mediated by a cannabinoid receptor (such as CB1 or CB2) are further provided.
TW096106748A 2006-02-27 2007-02-27 Bicyclic heteroaryl derivatives as cannabinoid receptor modulators TW200745126A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN275MU2006 2006-02-27
US78105506P 2006-03-10 2006-03-10
IN1146MU2006 2006-07-18
US82147506P 2006-08-04 2006-08-04
IN2088MU2006 2006-12-20

Publications (1)

Publication Number Publication Date
TW200745126A true TW200745126A (en) 2007-12-16

Family

ID=38437745

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096106748A TW200745126A (en) 2006-02-27 2007-02-27 Bicyclic heteroaryl derivatives as cannabinoid receptor modulators

Country Status (4)

Country Link
AR (1) AR059643A1 (en)
PE (1) PE20080114A1 (en)
TW (1) TW200745126A (en)
WO (1) WO2007096764A2 (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021781A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
DK3034075T3 (en) 2006-11-22 2018-10-22 Incyte Holdings Corp IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASEI INHIBITORS
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2009032754A2 (en) * 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
LT2300455T (en) 2008-05-21 2017-11-10 Incyte Holdings Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
CA2743134A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8299073B2 (en) 2008-12-11 2012-10-30 Respivert Ltd. P38 MAP kinase inhibitors
CA3013000C (en) 2008-12-19 2022-12-13 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
WO2010079241A1 (en) * 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability
EP2419429B1 (en) 2009-04-16 2014-03-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines as inhibitors of protein kinases
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
CA2788398C (en) 2010-02-03 2018-02-27 Incyte Corporation Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
EP2569313A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143425A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013529200A (en) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
JP2013526539A (en) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazines useful as ATR kinase inhibitors
AU2011253021A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of ATR kinase
CA2803802A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
KR101326557B1 (en) * 2011-03-31 2013-11-08 주식회사종근당 Benzamide derivatives as cannabinoid cb1 receptor antagonists
EP2694498B1 (en) 2011-04-05 2016-03-30 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
EP3733185B1 (en) 2011-09-30 2022-12-07 Vertex Pharmaceuticals Incorporated Treating non-small cell lung cancer with atr inhibitors
EP2751099B1 (en) 2011-09-30 2017-06-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PT2940017T (en) 2011-09-30 2019-10-31 Vertex Pharma Process for making compounds useful as inhibitors of atr kinase
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
ES2588186T3 (en) 2012-01-10 2016-10-31 Bayer Intellectual Property Gmbh Imidazopyrazines substituted as Akt kinase inhibitors
CN108478577A (en) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 It can be used as the compound of ATR kinase inhibitors and combinations thereof therapy
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PT2925757T (en) 2012-11-19 2018-01-09 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
SI3808749T1 (en) 2012-12-07 2023-07-31 Vertex Pharmaceuticals Incorporated Pyrazolo(1,5-a)pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
CN103012284A (en) * 2012-12-26 2013-04-03 无锡捷化医药科技有限公司 Preparation method of 2-amino-5-bromopyrimidine compound
MA38287B1 (en) 2013-01-23 2018-08-31 Astrazeneca Ab New aminopyrazine derivatives for the treatment or prevention of cancer
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
SI3077397T1 (en) 2013-12-06 2020-02-28 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-n-(5-fluoro-pyridin-3-yl)pyrazolo(1,5-a)pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
PL3152212T3 (en) 2014-06-05 2020-06-15 Vertex Pharmaceuticals Inc. Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
SI3157566T1 (en) 2014-06-17 2019-08-30 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
MA52119A (en) 2015-10-19 2018-08-29 Ncyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
EP3377488B1 (en) 2015-11-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3394033T2 (en) 2015-12-22 2021-04-30 Incyte Corp Heterocyclic compounds as immunomodulators
AR108396A1 (en) 2016-05-06 2018-08-15 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
MA45116A (en) 2016-05-26 2021-06-02 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
JP7000357B2 (en) 2016-06-20 2022-01-19 インサイト・コーポレイション Heterocyclic compounds as immunomodulators
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US10000500B2 (en) 2016-07-28 2018-06-19 Promega Corporation Coelenterazine analogues
CN106317043B (en) * 2016-08-19 2018-11-02 成都理工大学 A kind of 2 agonist of Cannabined receptor
CN106317059B (en) * 2016-08-19 2018-10-12 成都理工大学 A kind of 2 (CB2) agonist of Cannabined receptor
MA46045A (en) 2016-08-29 2021-04-28 Incyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
JP7101678B2 (en) 2016-12-22 2022-07-15 インサイト・コーポレイション Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MD3558990T2 (en) 2016-12-22 2023-02-28 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as PD-L1 internalization inducers
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
AU2019245288C1 (en) 2018-03-30 2024-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
PE20211918A1 (en) 2018-05-11 2021-09-28 Incyte Corp TETRAHYDRO-IMIDAZO [4,5-C] PYRIDIN DERIVATIVES AS PD-L1 IMMUNOMODULATORS
GB201811695D0 (en) 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
EP4037773A1 (en) 2019-09-30 2022-08-10 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
WO2021096849A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
TW202233615A (en) 2020-11-06 2022-09-01 美商英塞特公司 Crystalline form of a pd-1/pd-l1 inhibitor
AR124001A1 (en) 2020-11-06 2023-02-01 Incyte Corp PROCESS FOR MANUFACTURING A PD-1 / PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF
WO2024023266A1 (en) * 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) * 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
ES2140354B1 (en) * 1998-08-03 2000-11-01 S A L V A T Lab Sa IMIDAZO (1,2A) AZINAS SUBSTITUTED AS SELECTIVE INHIBITORS OF COX-2.
JP4025468B2 (en) * 1999-07-29 2007-12-19 三井化学株式会社 Organic electroluminescence device
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
EA009038B1 (en) * 2003-07-30 2007-10-26 Лабораториос С.А.Л.В.А.Т., С.А. Substituted imidazopyrimidines for the prevention and treatment of cancer

Also Published As

Publication number Publication date
WO2007096764A2 (en) 2007-08-30
AR059643A1 (en) 2008-04-16
PE20080114A1 (en) 2008-04-16
WO2007096764A3 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
TW200745126A (en) Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
MY142409A (en) Novel cannabinoid 1 or cannabinoid 2 receptor modulators, pharmaceutical compositions containing them, and process for their preparation
WO2009010455A3 (en) Pyrazole derivatives as modulators of metabotropic glutamate receptors
AU2003276028A1 (en) Pyridine derivatives as cb2 receptor modulators
ZA200807986B (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
MX2009006339A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity.
WO2007076070A3 (en) Modulators of muscarinic receptors
UA83194C2 (en) Pyrimidine derivatives and their use as cb2 modulators
WO2005080343A3 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
MX2009003981A (en) Calcium receptor modulating agents.
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
EP2010179A4 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
EP2010178A4 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2008053341A3 (en) Bridged bicyclic indazoles as cannabinoid receptor ligands
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
WO2008005908A3 (en) Pyridoimidazole derivatives
WO2009051718A3 (en) Calcium receptor modulating agents
WO2007058805A3 (en) Compositions and methods for treating cns disorders
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex
ATE407119T1 (en) PYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF THE CB2 RECEPTOR
WO2008035356A3 (en) Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
ATE484506T1 (en) SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESINE RECEPTOR SUBTYPE 3 MODULATORS
MX2009004112A (en) Substituted imidazoles as bombesin receptor subtype-3 modulators.
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2008051404A3 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators